GlassScriptPhysician profile
Fidelis Moseri
NPI 1275916611
$4,774.27
in general payments reported to CMS, 2019-2025
17 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $781 · 2022: $778 · 2023: $1,280 · 2024: $777 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,368.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $735.89 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $659.26 | 2021-2025 | Caplyta |
| Alkermes, INC. | $600.61 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $303.36 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $300.71 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $200.34 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $129.32 | 2021-2022 | |
| Corium, LLC | $101.37 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $85.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.98 | 2022-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $49.62 | 2021-2025 | Ingrezza |
| Neuronetics, INC. | $43.94 | 2023 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $40.14 | 2021-2023 | Spravato |
| Eisai INC. | $33.88 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.90 | 2021 | |
| Vanda Pharmaceuticals INC. | $22.86 | 2024 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fidelis Moseri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.